Mycobacterium leprae: Microbiology, Pathogenesis, and Clinical Spectrum

Mycobacterium leprae — the causative agent of leprosy (Hansen's disease) — is an obligate intracellular acid-fast bacillus with unique features:

Microbiological Characteristics

  • Gram-positive (but stains poorly; use Ziehl-Neelsen or Fite-Faraco)
  • Rod-shaped, 1–8 µm × 0.3–0.5 µm
  • Non-motile, non-spore-forming
  • Obligate intracellular parasite (cannot grow on artificial media)
  • Extremely slow generation time: 12–14 days (vs. 20 min for E. coli)
  • Optimal growth at 30–33°C (prefers cooler tissues: skin, peripheral nerves, upper respiratory mucosa, testes)
  • Genome reduction: ~3.3 Mb, >50% pseudogenes — massive reductive evolution

Pathogenesis in Host

  1. Entry via respiratory droplets or broken skin.
  2. Phagocytosed by dermal macrophages and Schwann cells.
  3. Survives intracellularly by inhibiting phagolysosome fusion, modulating host apoptosis, and scavenging host metabolites.
  4. Replicates slowly → logarithmic growth takes months.
  5. Destroys macrophages → spreads to adjacent cells and along nerves (centripetal).
  6. Immune response determines clinical pole:
    • Tuberculoid (paucibacillary): Strong CMI → few lesions, high immunity, few bacilli.
    • Lepromatous (multibacillary): Weak CMI → disseminated lesions, high bacillary load, systemic involvement.

Clinical Manifestations

  • Hypopigmented/anesthetic skin patches
  • Peripheral nerve thickening (ulnar, median, common peroneal, posterior tibial)
  • Loss of sensation → trauma, ulcers, deformities
  • Eye involvement (lagophthalmos, corneal anesthesia, uveitis → blindness)
  • Testicular atrophy → infertility
  • Type 1 (reversal) and Type 2 (ENL) reactions — immune-mediated flares

Treatment

WHO MDT (multi-drug therapy): Dapsone + Rifampicin ± Clofazimine (6–12 months). Early treatment prevents disability. Drug resistance monitoring essential.

Lyme Disease - Related Articles